Advice
in the absence of a submission from the holder of the marketing authorisation:
lenalidomide (Revlimid®) is not recommended for use within NHSScotland.
Indication under review: as combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Note: SMC advice 1096/15 is still valid.
Download detailed advice358KB (PDF)
Medicine details
- Medicine name:
- lenalidomide (Revlimid)
- SMC ID:
- SMC2217
- Indication:
As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 August 2019